Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents – Dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study-Reference-Cited by-同舟云学术

Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents – Dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study

Published:2014-08 Issue:12 Volume:50 Page:2040-2049
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Postel-Vinay Sophie,Collette Laurence,Paoletti Xavier,Rizzo Elisa,Massard Christophe,Olmos David,Fowst Camilla,Levy Bernard,Mancini Pierre,Lacombe Denis,Ivy Percy,Seymour Lesley,Le Tourneau Christophe,Siu Lillian L.,Kaye Stan B.,Verweij Jaap,Soria Jean-Charles

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference18 articles.

1. Critical role of phase I clinical trials in cancer treatment;Oncology;J Clin Oncol,1997

2. Dose escalation methods in phase I cancer clinical trials;Le Tourneau;J Natl Cancer Inst,2009

3. Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?;Postel-Vinay;J Clin Oncol,2011

4. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?;Gelmon;J Natl Cancer Inst,1999

5. Development of target-based antineoplastic agents;Stadler;Invest New Drugs,2000

Cited by 105 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association between body composition phenotypes and treatment toxicity in women with cervical cancer undergoing chemoradiotherapy;Nutrition;2024-11

2. Dose Optimization of Targeted Therapies for Oncologic Indications;Cancers;2024-06-09

3. Assessing patient risk, benefit, and outcomes in drug development: A decade of ramucirumab clinical trials;Cancer Medicine;2024-05

4. Estimands in Oncology Early Clinical Development: Assessing the Impact of Intercurrent Events on the Dose-Toxicity Relationship;Statistics in Biopharmaceutical Research;2023-12-18

5. Gene polymorphisms affect postoperative imatinib plasma levels and edema in adults with gastrointestinal stromal tumor;Pharmacogenomics;2023-05